Atlas Trials

CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Clinical trial NCT07763938 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07763938
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory B-cell Malignancies
Start date
2026-11-01
Primary completion
2029-12-30
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.